Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as an injectable solution for intravenous use. It is employed in the treatment of certain advanced solid tumours, notably non‑small cell lung cancer and metastatic breast cancer, in adult oncology patients.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable logistics for hospital pharmacies and cancer treatment facilities across global markets, ensuring timely delivery and regulatory compliance.

Vinorelbine is indicated for specific solid tumour types within the oncology therapeutic pathway.

Non‑small cell lung cancer: used to improve progression‑free survival in adult patients with advanced disease. Metastatic breast cancer: employed to control disease progression in patients previously treated with anthracyclines and taxanes.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Nausea and vomiting: gastrointestinal upset common after infusion. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary. - Constipation: decreased bowel movements. - Anemia: lowered red blood cell levels causing weakness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe pulmonary toxicity: breathlessness or interstitial pneumonitis. - Peripheral neuropathy: tingling or numbness in extremities. - Cardiac toxicity: arrhythmias or reduced cardiac function. - Anaphylactic reactions: severe allergic response needing immediate treatment. - Thrombocytopenia: low platelet count leading to bleeding risk.

Vinorelbine requires careful monitoring and specific safety measures before and during therapy.

Monitor blood counts: perform regular CBCs to detect neutropenia and anemia. Assess liver function: adjust dosing in patients with hepatic impairment. Avoid concurrent myelosuppressive agents: reduce risk of severe bone‑marrow suppression. Use anti‑emetics prophylactically: mitigate nausea and vomiting associated with infusion. Pregnancy and lactation: contraindicated unless benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase vinorelbine exposure. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce therapeutic levels. - Concurrent myelosuppressive chemotherapy: heighten risk of severe neutropenia. - Live vaccines: risk of infection due to immunosuppression. - Other Vinca alkaloids: additive neurotoxicity.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may alter QT interval. - Anticoagulants (warfarin, DOACs): monitor coagulation parameters. - Diuretics: watch for electrolyte disturbances. - CYP2D6 substrates: possible modest effect on metabolism.